Search
forLearn
5 / 801 resultslearn Biotinyl-GHK
learn biovolume 128
learn amino acids blend
learn multipeptides
Research
5 / 1000+ resultsresearch Carbobenzoxy-capped Phe-Lys(BODIPY TMR-X-acyloxymethyl ketone(QSY7)
Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.
research Engineered Skin Substitute Regenerates the Skin with Hair Follicle Formation
The engineered skin substitute helped grow skin with hair on mice.
research Engineered exosomes and composite biomaterials for tissue regeneration
Exosomes show promise for future tissue regeneration.
research Improved forensic hair evidence for drugs of abuse by mass spectrometry
Forensic hair analysis for drugs is now more reliable and accurate.
research Protein Microarrays
Protein microarrays are highly sensitive tools useful for disease diagnosis and studying proteins.
Community Join
5 / 1000+ resultscommunity Binding affinity does not equal potency for anti androgens? Comparing pyrilutimide to cb-03-01
Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.
community Binding affinity of pyrilutamide!
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.
community Pyrilutamide binding affinity is similar to RU
Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.
community Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.